Nature, Published online: 26 October 2022; doi:10.1038/s41586-022-05368-8
Patients with resectable clinical stage III or oligometastatic stage IV melanoma were given neoadjuvant relatlimab and nivolumab combination immunotherapy, which induced a high pathologic complete response rate, indicating the efficacy and safety of this regimen.
More News
Author Correction: Stepwise activation of a metabotropic glutamate receptor – Nature
Changing rainforest to plantations shifts tropical food webs
Streamlined skull helps foxes take a nosedive